AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Innovative Research: Oxford Nanopore will analyze 50,000 UK Biobank samples to investigate disease mechanisms through epigenetic sequencing.
- Cutting-Edge Technology: Comprehensive methylation marker insights provided without complex chemical processes.
- Strategic Growth: Partnerships align with the Group’s target of 30% annual revenue growth between FY24 and FY27.
Oxford Nanopore Technologies plc (LSE:ONT) has announced a pioneering collaboration with UK Biobank to develop the first comprehensive large-scale epigenetic dataset. This groundbreaking initiative aims to unlock critical insights into the mechanisms behind diseases such as cancer, neurodegenerative disorders, and other complex conditions.
Project Overview
Oxford Nanopore will deploy its advanced nanopore-based molecular sensing technology to sequence the epigenome of 50,000 participant samples. The research will use 15-30x sequencing coverage to explore potential causes of diseases, focusing on how external factors and lifestyle choices influence DNA and gene expression.
This study, set to run for up to 24 months, is poised to generate a wealth of data by identifying up to 98% of epigenetic methylation markers. Unlike traditional sequencing technologies, Oxford Nanopore’s approach eliminates the need for complex chemical processes like bisulfite conversion, making it a more streamlined and comprehensive solution for epigenetic analysis.
Epigenetics: Unlocking Disease Insights
Epigenetics examines how environmental and lifestyle factors can modify DNA, affecting gene expression and influencing disease risk. Understanding these changes could provide breakthroughs in diagnosing and treating conditions such as cancer and neurodegeneration.
Strategic Implications
This collaboration builds on Oxford Nanopore’s existing initiatives, including its partnership with the UK Government to establish a real-time biosurveillance system across NHS England. That system aims to create an early warning network for emerging pandemics and biological threats.
Despite the scale and importance of these projects, the company has reaffirmed its financial guidance. Incremental revenues from these partnerships will support Oxford Nanopore’s goal of achieving a compound annual growth rate (CAGR) exceeding 30% between FY24 and FY27, in constant currency terms.
